2025-02-142025-02-142025-02-13Torres, J., Valenzuela Oses, J.K., Rabasco Álvarez, A.M., González Rodríguez, M.L. y García, M.C. (2025). Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers. Pharmaceutics, 17 (2), 245. https://doi.org/10.3390/pharmaceutics17020245.1999-4923https://hdl.handle.net/11441/168697Recent advancements in nanotechnology have revolutionized cancer therapy—one of the most pressing global health challenges and a leading cause of death—through the development of liposomes (L), lipid-based nanovesicles known for their biocompatibility and ability to encapsulate both hydrophilic and lipophilic drugs. More recent innovations have led to the creation of stimuli-responsive L that release their payloads in response to specific endogenous or exogenous triggers. Dual- and multi-responsive L, which react to multiple stimuli, offer even greater precision, improving therapeutic outcomes while reducing systemic toxicity. Additionally, these smart L can adjust their physicochemical properties and morphology to enable site-specific targeting and controlled drug release, enhancing treatment efficacy while minimizing adverse effects. This review explores the latest advancements in endogenous stimuli-responsive liposomal nanocarriers, as well as dual- and multi-responsive L that integrate internal and external triggers, with a focus on their design strategies, mechanisms, and applications in cancer therapy.application/pdf36 p.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/lipid vesiclesstimuli-sensitive nanocarrierscancer nanomedicinedrug deliveryinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.3390/pharmaceutics17020245